Selank
Compoundable (Rx)Nootropic Peptides · Anxiolytic
Selank is a synthetic analog of the naturally occurring immunomodulatory peptide tuftsin, developed at the Russian Institute of Molecular Genetics alongside Semax.
What is Selank?
Selank is a synthetic analog of the naturally occurring immunomodulatory peptide tuftsin, developed at the Russian Institute of Molecular Genetics alongside Semax. It is approved in Russia as an anxiolytic and nootropic. It combines anti-anxiety effects with cognitive enhancement without sedation or addiction potential.
Also known as: TP-7
How Does Selank Work?
Modulates GABA-A receptor expression, enhances serotonin metabolism, and stabilizes brain enkephalins. Increases IL-6 expression and modulates the balance of T-helper cell cytokines. Provides anxiolytic effects through GABAergic enhancement without benzodiazepine-like sedation or dependence.
What is Selank Used For?
- Anxiety reduction
- Cognitive enhancement
- Immune modulation
- Stress management
Potential Side Effects
- Nasal irritation
- Fatigue (rare)
- Mild allergic reactions (very rare)
Contraindications
- Pregnancy
- Autoimmune conditions
- Children
FDA Legal Status
United States — FDA
Compoundable (Rx)Category 1 (restored 2026)
Related Peptides
Semax
Compoundable (Rx)Nootropic Peptides
Semax is a synthetic peptide derived from ACTH (adrenocorticotropic hormone, fragment 4-10) developed by the Russian Ins...
DSIP
Compoundable (Rx)Nootropic Peptides
DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring neuropeptide that promotes delta wave (deep) sleep. It was ...
Head-to-head comparisons:
Frequently Asked Questions
How does Selank compare to benzodiazepines?
Can you take Selank and Semax together?
Quick Facts
- Legal Status (USA)
- Compoundable (Rx)
- FDA Category
- Category 1 (restored 2026)
- Evidence Rating
- BModerate Evidence (Some Human Data)
- Class / Subclass
- Nootropic Peptides / Anxiolytic
- Administration
- nasal, subcutaneous
- Typical Dosage
- 250-500mcg nasal, 1-3x daily
- Half-Life
- ~5-10 minutes (rapid onset, sustained effects)
- Year Discovered
- 1996
Sources
Last updated: 2026-04-01
Sources & references
Primary sources used for the dosing, mechanism, side-effect, and regulatory claims on this page. Verify time-sensitive information (regulatory status, prescribing details) on the source before relying on it for medical decisions. See our disclaimer.
- PubMed PMID 18577768 — peer-reviewed primary literature on Selank.
- FDA Federal Register — official notice record for FDA regulatory actions and Category 1 / 503A bulk-substance updates.